Search
SRP 299
go.drugbank.com/drugs/DB05440ExperimentalA specific subset of serotonergic neurons in the interfascicular part of the dorsal raphe nucleus (DRI) is believed to be involved, based on studies with mice. … SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation.
AVAC
go.drugbank.com/drugs/DB05441Experimental[Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate
Iroxanadine
go.drugbank.com/drugs/DB05444ExperimentalBRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … EC function plays a central role in vascular diseases (e.g. atherosclerosis, restenosis, diabetic angiopathies, microvascular angina, peripheral arterial disease).
SR 121463
go.drugbank.com/drugs/DB05455InvestigationalSR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
OSI-7904L
go.drugbank.com/drugs/DB05457InvestigationalOSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA).
Chlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalIt is a synthetic version of a neurotoxin isolated from the venom of the Giant Yellow Israeli scorpion Leiurus quinquestriatus. … Chlorotoxin is a small 36-amino-acid peptide that selectively binds to glioma cells but not normal brain parenchyma.
Palovarotene
go.drugbank.com/drugs/DB05467Approved], which are derivatives of [vitamin A]. … It first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP.
Brentuximab
go.drugbank.com/drugs/DB05471InvestigationalSGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … Brentuximab (SGN-30) is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared
T487
go.drugbank.com/drugs/DB05474ExperimentalT487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3.
CZEN 002
go.drugbank.com/drugs/DB05479ExperimentalIt has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. … CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses.